Molycorp (MCP) Demand Improves but Co. Not Out of Woods on Pricing
Tweet
Share
E-mailGet Alerts MCP Hot Sheet
Price: $0.36 --0%
Rating Summary:
2 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Rating Summary:
2 Buy, 6 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Join SI Premium – FREE
Goldman Sachs today maintained a Neutral rating on Molycorp (NYSE: MCP) with a price target of $6.00. Molycorp reported Q1 results yesterday. Commenting, analyst Brian Lee noted that rare earth demand was normalizing, but pricing and execution were still a challenge.
"Molycorp's outlook for REO pricing appears to be less than constructive, as according to management illegal Chinese production and smuggling remains prevalent despite a concerted crackdown by Beijing. This increases the importance of being a low cost producer, which for Molycorp requires the integration of its chlor-alkali plant, a facility not expected to come online until late-2013," said Lee.
"We see near-term catalysts to potentially become more constructive revolving around: (1) improvement in production cost visibility, (2) further balance sheet support in the form of an expected $125mn revolver, and/or (3) positive trial results for Sorbx," added the analyst.
For an analyst ratings summary and ratings history on Molycorp (NYSE: MCP) click here. For more ratings news on Molycorp click here.
Shares of Molycorp closed at $5.59 yesterday.
"Molycorp's outlook for REO pricing appears to be less than constructive, as according to management illegal Chinese production and smuggling remains prevalent despite a concerted crackdown by Beijing. This increases the importance of being a low cost producer, which for Molycorp requires the integration of its chlor-alkali plant, a facility not expected to come online until late-2013," said Lee.
"We see near-term catalysts to potentially become more constructive revolving around: (1) improvement in production cost visibility, (2) further balance sheet support in the form of an expected $125mn revolver, and/or (3) positive trial results for Sorbx," added the analyst.
For an analyst ratings summary and ratings history on Molycorp (NYSE: MCP) click here. For more ratings news on Molycorp click here.
Shares of Molycorp closed at $5.59 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Starts Dollarama Inc. (DOL:CN) (DLMAF) at Buy
- McGraw Hill (MH) PT Lowered to $14 at UBS on Softer 2027 Outlook
- Glenmark Pharmaceuticals Ltd. (GNP:IN) PT Raised to INR2,750 at Investec
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
